

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Dec 08, 2021

Source URL: <https://www.novartis.com/us-en/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer-0>

List of links present in page

- <https://www.novartis.com/us-en/us-en/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer-0>